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Bypassing bureaucracy to answer important questions 
quickly  
 
Jonathan Emery-Barker; Iain McClure; Alison Wood; Rachel Robertson; David Young and 
Helen Minnis 
 
 
 
 
“Bureaucracy is a parasite that preys on free thought and suffocates free spirit”   
Douglas Adams  
So Long and Thanks for All the Fish (1984) 
 
Introduction 
Sometimes there is a need to answer important clinical questions quickly. Bureaucracy can 
erect an insurmountable barrier.  The Research Governance Framework (RGF) for Health 
and Social Care was introduced in England in 2005 aiming to improve the efficiency and 
quality of research in the NHS, but has unwittingly introduced a new layer of bureaucracy 
which is preventing some important questions being answered.  
 
We attempted to survey prescribing practices among UK psychiatrists in response to an 
urgent need for this information.  There was huge variation between the responses of 
Research and Development (R&D) offices and our capacity to address the requirements of 
each office was overwhelmed.  R&D approval can now be impossible to obtain.  This 
implies the need for a radical rethink of the system. Scotland is now leading the way in the 
development of the first UK Multicentre R&D committee which aims to create a 
standardised and more simple system.   
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The question we tried to answer 
In December 2003, the Committee on Safety of Medicines (CSM) issued guidelines 
suggesting that Fluoxetine was the only safe antidepressant for use in child and adolescent 
depression.  We were aware that our clinical colleagues were struggling with having to 
implement an immediate and radical change in their practice and we wanted to find out 
how they (and, by inference, their patients) were coping with this.  We knew that this was 
an important and urgent clinical question.  We wanted to avoid bureaucratic and practical 
barriers and therefore, after obtaining a small grant from our local health board, we 
designed and piloted a simple questionnaire (taking no more than 10 minutes for clinicians 
to complete) and obtained MREC approval.   
 
Our past experience had shown us that national survey research could be an efficient way 
for busy NHS clinicians to answer important questions that arose from clinical practice and 
which had the potential to influence future service development (1;2). Any research by 
NHS clinicians must be reviewed by the NHS R&D system before the research can be 
implemented and we realised that this was intended to be a supportive system designed to 
enable safe and cost-effective research in the NHS (3). We were therefore dismayed by the 
subsequent insurmountable bureaucratic barrier erected by NHS R&D nationally, which 
resulted in us having to abandon the study. 
 
The question we succeeded in answering 
 
Not to be defeated, we decided, instead, to ask the question “how did bureaucracy force us 
to abandon our study?”. 
 
In 2000, the English Department of Health released guidelines entitled the Research 
Governance Framework (RGF) for Health and Social Care (3) which were intended to 
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improve the quality of research, improve patients’ rights, ensure financial control and 
accountability and prevent the investigation or publication of substandard or fraudulent 
work.  The guidelines state that health care bodies must “be aware of research conducted in 
or through their organisation” and that, “no study should begin until a person with 
authority to do so has given written permission”.   
 
However, as our study was low risk, specific written approval by R&D offices other than 
our local one was not deemed necessary by the Multicentre Research Ethics Committee 
(MREC). MREC recommended that we should “arrange that all relevant care organisations 
to be notified that the research will be taking place”.  Being a national survey, our research 
was the remit of all R&D offices in the UK.  Ordinarily, this requirement would have 
prevented a low-budget study such as ours proceeding, but our local R&D department was 
determined that their system should not impede research.  They sent out a research pack, 
on our behalf, to each of the 604 UK R&D offices containing a covering letter, a copy of 
the local NHS R&D Management approval letter, a protocol for the study and a copy of the 
MREC approval letter.  From our interpretation of the RGF, we were simply notifying 
everyone and planned to begin data collection shortly thereafter. 
 
However, nearly one-third of all primary care trusts (PCTs) then requested further 
information.  This led us to doubt whether non-responders (57% of the PCTs) had accepted 
the notion of simple notification and to wonder whether our notification had triggered an 
automatic and complex process of approval.  To our dismay, we found ourselves in the 
midst of a slowly emerging and eventually insurmountable bureaucratic response from the 
R&D departments, with an alarmingly wide variation in interpretations of the RGF, as 
demonstrated in Figure 1.  Some trusts requested documents in electronic format instead of 
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the supplied paper format.  Others required unique local R&D forms, or forms which were 
additional to the standard national format.  A number of documents requested were 
inappropriate for a survey of professionals including patient information sheets, 
introductory letters to GPs and requests for various parts of the ethics form which were 
either already included or not required.  Some offices asked us to supply the names of the 
consultant psychiatrists that were to be involved in the research in their area, even though 
our covering letter stated that we did not have this level of detail in our database.  One 
English R&D office required that all members of the Scottish research team apply for 
honorary clinical contracts in their Hospital Trust.   
 
These requests suggest that a “one size fits all” approach had been taken by many R&D 
offices and that individual review of each study had either not been done or had been done 
by members of staff who were ill-equipped to evaluate levels of risk posed by different 
types of research.   
 
Figure 1 
The survival graph in Figure 2 shows that after 70 days, we only had formal approval from 
15% of PCTs.  From the shape of the curve, it is clear that our study would never have 
gained approval from all the relevant parties, at least within our research project’s lifetime.  
Reluctantly, we realised that our urgent and important question had been condemned to a 
bureaucratic trashcan. 
 
 
Figure 2 here 
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The silver lining 
We (the research team and our local R&D department) felt that this must never happen 
again. We looked for precedents in which other systems had successfully removed 
unnecessary bureaucracy and found a useful model in Multicentre Research Ethics 
Committees.  Variations in the functioning of ethics committees had erected barriers to 
research and a new system of multi-centre ethics approval was introduced in the UK during 
the last decade to address some of the problems highlighted by researchers when 
undertaking studies involving more than one site (4).  The use of standardised means of 
assessment by the new multi-centre research ethics committees means that their approval is 
transferable throughout the entire United Kingdom (5).   
 
Local R&D offices are now throwing up the same barriers that local research ethics 
committees once were and currently constitute the major barrier to multi-site research (5) 
(6). MREC had managed to achieve a national system, so, we asked ourselves, could R&D 
keep up?  We attempted to drive forward a national response to the problem by describing 
our abandoned study to key UK policy figures however, despite significant efforts, it 
proved impossible to influence change in the system for the UK as a whole. Fortunately the 
Scottish R&D Consortium was more receptive, and, as a direct result of our findings, a 
Multi-Centre Research And Development Office is now being piloted in Scotland that will 
create a standardised system north of the border. 
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What are the arguments for MRAD? 
Cost: We have found that to cover all the requests of R&D offices, 11 different 
documents (Fig 3) would be required.  For each local UK R&D office to have a copy of 
all the information which they currently require, we estimate the costs (human 
resources and consumables) to be around £20 per application i.e. £12, 000 in total.  At 
such a price, this kind of MREC-approved national survey research can no longer be 
the domain of the busy clinician using funds from small NHS endowments or slush 
funds.  There are already some R&D systems in place that aim to improve the situation.  
The North Yorkshire NHS R&D Alliance, for example, has combined six trust R&D 
offices and is able to manage all research projects in North Yorkshire, cutting down on 
paperwork.   
 
Standardisation: The makeup of the staff of R&D departments is variable in terms of 
skills and levels of experience.  This may account for the range of replies which we 
received and the varying time taken for approval.  Some offices have no scientifically 
trained risk assessment officers and may be unreasonably cautious with studies that 
they lack the skills to adequately assess.  
 
How will the new committee work? 
MRAD will be made up of R & D Managers and R & D Co-ordinators from offices 
throughout Scotland.  Members will be experienced in the field of research and have a 
range of skills such as finance, statistics, ethics, risk assessment and 
clinical/pharmaceutical knowledge.  The committee will meet twice per month and 
appropriate staff will serve on the committee on a rotational basis. R & D Offices that will 
be involved in the study will be on the review committee. A lead reviewer for each project 
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will be identified from the sites involved and it will be the lead reviewer only that will 
liaise with the applicant to resolve any issues relating to the project. MRAD will carry out 
the generic review leaving only local issues to be approved by the local offices.   The 
researcher will benefit as all R & D issues & paperwork will be dealt with at the outset by 
one contact, clarified and then disseminated to all applicable sites. As each Health Board in 
Scotland is a legal entity in it’s own right they must give final approval, however each 
board will shortly be asked to sign up to a Memorandum of Understanding in which they 
will agree to abide by the MRAD review and standardised paperwork. 
 
The individual R&D offices will still be entitled to reject a favourable MRAD review but 
only if a local issue is recognised that had not been appreciated by the committee.  It would 
be helpful if the MRAD system, as it develops, is overtly linked to the MREC system so 
that there is a “one-door entry” system for researchers and so that MRADs follow the same 
strict time frame of approval as MRECs. There is some evidence that the MREC system 
has improved the time taken to approval (4) and we would hope that the MRAD system 
would do the same. 
 
The newly developing Scottish MRAD is attempting to incorporate all of these features.  
The pilot scheme is underway with plans to roll out to the whole of Scotland by the end of 
2007.   
 
Conclusion 
For each member of our research and local R&D team, this was our first experience of 
being forced to abandon the investigation of an urgent and important clinical question 
because of bureaucracy.  Luckily our sad tale appears to have resonated with our 
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colleagues in R&D offices across Scotland and has allowed us to pull together in an 
attempt to change the system to the benefit of researchers and, most importantly, patients.  
A UK-wide MRAD would considerably enhance the efficiency of clinical research.  We 
can see no sensible reason why, if this can be achieved in Scotland, it cannot be achieved 
nationally.   
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Summary Box 
 
 
• The Research Governance Framework has unwittingly introduced an 
insurmountable new layer of bureaucracy 
• A nationwide survey of psychiatric prescribing practice was impossible 
under the RGF 
• Our experience of this bureaucratic barrier stimulated us to undertake a 
study of the R&D system nationwide 
• As a result of our study, a new Multicentre Research and Development 
(MRAD) approach has been introduced in Scotland along the lines of 
the Multicentre Research Ethics Committee system 
• The Scottish MRAD innovation should be rolled out nationally 
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Figure 3 – documents currently required for local R&D office approval 
  
 
• covering letter 
• copy of MREC application and approval letter 
• national R&D form 
• sponsorship confirmation 
• indemnity form 
• copy of survey instruments 
• CV of all researchers 
• all of the above in electronic format and hard copy 
• local R&D forms 
• data protection forms 
• evidence of peer review 
